▷ Founding of Mozart Therapeutics: USD 55 million in Series A funding to …


27.10.2021 – 03:32

Mozart Therapeutics

Seattle (ots/PRNewswire)

– Further development of first-class CD8 Treg modulators to restore immune imbalance

Mozart Therapeutics, Inc., a newly formed biopharmaceutical company specializing in a novel immune pathway to alter the course of autoimmune and inflammatory diseases, today announced a $ 55 million Series A funding led by Seed and Series A Investor ARCH Venture Partners announced together with Sofinnova Partners. Other investors include Eli Lilly & Company, MRL Ventures Fund (the early stage fund of Merck & Co., Inc.), Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments.

Mozart was founded on the groundbreaking work of Mark M. Davis, PhD, a leading world expert in T-cell biology. Professor Davis found that a CD8-T regulatory cell network plays a key role in the monitoring, detection and elimination of inappropriately activated autoreactive and pathogenic immune cells that are a cause of autoimmune and inflammatory diseases.1 Mozart was licensed for this technology, to develop therapeutic candidates that target and modulate this network for the treatment of autoimmune and inflammatory diseases.

The company will use the Series A funding to bring its leading CD8 Treg modulator to the clinic while promoting additional programs generated on its novel platform.

“Mozart is doing a unique job changing the treatment paradigm for patients with autoimmune and inflammatory diseases. Our goal is to rebalance the immune system by using a new avenue to use world-class CD8 Treg modulators as disease-modifying therapeutics to meet an unmet need in a wide range of diseases, “said Katie Fanning, CEO of Mozart Therapeutics, who has been in the biotech industry for 35 years. “I am grateful to have the financial backing of a strong consortium of high-profile healthcare investors who contribute exceptional industry and strategic guidance to help our therapeutic candidates move forward in development and into the clinic.”

“The modulation of the CD8-T-Reg network represents a novel way of addressing a fundamental cause of dysregulation in the immune system. We are pleased to be able to support the further development of Mozart’s innovative research disease significantly, “said Steve Gillis, PhD, managing director of ARCH Venture Partners and chairman of the board of Mozart.

“In view of the considerable and far-reaching need for effective therapeutic options for autoimmune and inflammatory diseases, it is exciting to see the novel and unique approach with which Mozart is meeting this challenge,” said Henrijette Richter, Managing Partner at Sofinnova Partners. “We are delighted to be able to join this first-class investor consortium and look forward to supporting the team in establishing Mozart as the world market leader in the modulation of CD8-T regulatory cells.”

Mozart also announced the formation of a Scientific Advisory Board (SAB) composed of outstanding opinion leaders in the fields of immunology, T-cell biology, immunomodulation and protein engineering, as well as its board of directors consisting of well-known veterans of the pharmaceutical industry and from the field of biotechnology Investments.

Mozart’s Scientific Advisory Board:

  • Mark M. Davis, Ph.D., Scientific Co-Founder, Director of the Stanford Institute for Immunology, Transplantation and Infection (ITI), Avery Family Professor of Immunology, and Researcher at the Howard Hughes Medical Institute.
  • K. Christopher Garcia PhD, Scientific Co-Founder, Professor of Molecular and Cellular Physiology and Structural Biology at Stanford University School of Medicine, and Researcher at Howard Hughes Medical Institute.
  • Calvin Kuo MD PhD, Scientific Co-Founder, Maureen Lyles D’Ambrogio Professor of Medicine (Hematology) at Stanford University School of Medicine
  • Michael Rosenblum, MD PhD, Professor of Dermatology and Vice Chair of Research at the University of California San Francisco (UCSF)

The Mozart Board:

  • Steven Gillis, PhD, chairman of ARCH Venture Partners
  • Tom Daniel, MD
  • Peter Dudek, PhD, MRL Ventures Fund
  • Julie Gilmore, PhD, Eli Lilly & Company
  • Lucio Iannone, PhD, Leaps by Bayer
  • Henrijette Richter, Sofinnova Partners

Information on CD8 Treg modulators

CD8-Treg modulators are disease-modifying therapeutic molecules that selectively target the CD8 regulatory T-cell network to counteract early events in the autoimmune inflammatory cascade. The dysregulation of this network plays a key role in the pathology of autoimmune and inflammatory diseases. CD8-Treg modulators were developed to restore the intrinsic functions of CD8-T regulatory cells and to suppress and eliminate pathogenic immune cells and to enable permanent control of autoimmune and other inflammatory diseases.

Information on Mozart Therapeutics

Mozart Therapeutics focuses on the development of disease-modifying therapies for autoimmune and inflammatory diseases that target a novel regulatory immune pathway. The therapeutic focus of Mozart’s lead program is autoimmune-mediated gastrointestinal diseases. The company is headquartered in Seattle, Washington state. For more information, visit www.mozart-tx.com and follow the company on LinkedIn @ Mozart-tx.

1Saligrama N, Davis MM et al., Nature 2019: https://doi.org/10.1038/s41586-019-1467-x

Press contact:

Julie Rathbun
Rathbun Communications
[email protected]
206-769-9219
Logo – https://mma.prnewswire.com/media/1669700/Mozart_Tagline_Color_RGB_Logo.jpg

Original content by: Mozart Therapeutics, transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published. Required fields are marked *